$NUVL

Lane Benjamin sold (to issuer) 36,553 shares of NUVL

Lane Benjamin (See Remarks) sold (to issuer) 36,553 shares of Nuvalent, Inc. (NUVL) across 2 trades on 2026-07-15.

Original reporting
SEC EDGAR · Lane Benjamin
Published Jul 15, 2026, 10:50 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 15, 2026, 10:55 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NUVL
Neutral
medium confidence
Mentioned
$NUVL
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NUVLNeutralLow
01

Why it matters

Insider selling can modestly pressure sentiment, but this specific disclosure lacks price/value and does not include operational or financial updates.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no new fundamental catalyst in the text.

03

What to watch

Price and total value are not disclosed, and the absence of a stated 10b5-1 plan does not, by itself, confirm insider conviction or timing intent.

Relevance 3/10Novelty 3/10Timing: Filed same day as the sale date, 2026-07-15.

Background

The article is an SEC Form 4 insider transaction disclosure for Nuvalent, Inc.

Company-level read

Ticker impact

$NUVLNeutralMedium confidence
Context

Nuvalent Form 4 shows officer Lane Benjamin sold 36,553 shares to the issuer on 2026-07-15, leaving 0 shares.

Expected impact

Low likelihood of a sustained price move; any reaction is likely short-lived unless paired with other disclosures.

Evidence & confidence

The filing is a primary-source Form 4, but the transaction is a sale with no price/value disclosed and no 10b5-1 plan stated, providing limited new information about company performance.

Market effects

No clear sector read-through from a single insider sale without additional company or industry catalysts.

None indicated.

None indicated.

Counterpoint

The sale could be administrative or liquidity-driven (sale to issuer) and may not reflect a bearish view on Nuvalent’s prospects.

Key entities

  • Nuvalent, Inc.

    Company whose Form 4 reports an officer sale to the issuer on 2026-07-15.

  • Lane Benjamin

    Officer who sold 36,553 shares to the issuer and reported 0 shares after the transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GSKMedAI 8/10

GSK completes acquisition of Nuvalent, Inc

GSK said it has completed its acquisition of Nuvalent (NASDAQ: NUVL) via a tender offer. The deal adds three lung cancer assets, including zidesamtinib (NVL-520) and neladalkib (NVL-655) under FDA review, plus NVL-330 in phase I. Transaction value is about $10.6B (£8.0B), net investment about $9.4B (£7.1B).

$MRVLMed

Stocks Erase Early Gains as Chipmakers Turn Lower

US stocks pared early gains as chipmakers and software firms fell. Marvell, Qualcomm, ARM and others dropped, while ServiceNow and Salesforce also declined. Treasury yields were pressured by a $58B 3-year auction and stronger May existing home sales. In Europe, Bund and gilt yields fell; swaps price a 100% chance of a 25 bp ECB hike. UNFI slid after Q3 sales missed; Nuvalent surged on a $10.6B GSK buyout.

$MUMed

More swings for AI stocks drag Wall Street back on the roller coaster

Wall Street swung as AI-related chip and memory stocks reversed after early gains. The S&P 500 fell 0.3% (7,386.65), the Nasdaq dropped 1% (25,678.82), and the Dow rose 0.2% (50,872.11). Micron slid 1.4% after a 10% drop; it had surged 9.9% Monday. Oil eased (Brent -3% to $91.45) but AI weakness outweighed. GSK agreed to buy Nuvalent for $10.6B, sending Nuvalent up 39.3%.

$COHRMed

Benzinga

U.S. stocks fell Tuesday as rotation out of chip and AI leaders resumed: Nasdaq 100 -3.3% to ~28,437, S&P 500 -1.6% to ~7,228, Dow -0.5% to ~50,535. Oil dropped ~6% and markets priced ~50% odds of a Fed hike by October ahead of Wednesday’s CPI. Tech led declines (XLK -5.1%); SMH fell as COHR -15.2%, MRVL -12.1%, LITE -11.8%.

$GSKHighAI 9/10

GSK Strikes $10.6B Nuvalent Deal Strengthening Targeting Cancer Pipeline

GSK agreed to acquire Nuvalent for $10.6B (£8.0B) to strengthen its late-stage oncology pipeline. GSK will tender for all Nuvalent shares at $124 cash, a 40% premium; net investment is $9.4B. Nuvalent’s FDA-review candidates Zidesamtinib and Neladalkib have 2026 decision dates. Deal expected to close in Q3 2026; GSK said 2026 outlook and 70p dividend remain unchanged.

$GSKHighAI 9/10

GSK Makes Its Biggest Bet In More Than A Decade, Paying $10. 6 Billion For Cancer Drug Developer Nuvalent

GSK will acquire Nuvalent for $10.6 billion, buying all outstanding shares for $124 cash each, a 40% premium to Nuvalent’s last close of $88.49. Nuvalent shares rose about 39% in premarket. GSK expects revenue growth and accretion to sales and core operating profit from 2027, and higher core EPS from 2029, gaining lung cancer assets including zidesamtinib and neladalkib.